INTRODUCTION {#sec1}
============

Sialic acids are found on all vertebrate cells, positioned at the terminal end of glycan chains that modify proteins and lipids. The most common sialic acid in animals is *N*-acetylneuraminic acid (Neu5Ac). In mammals, sialic acids perform a wide range of functions, such as cell-cell interactions and immune modulation ([@B1], [@B46]). Sialic acids also appear to have an immunological status as "self-associated molecular patterns" in mammals ([@B2], [@B47]). In fact, many bacterial pathogens synthesize or acquire sialic acids (Neu5Ac) and incorporate these molecules into surface structures, such as lipopolysaccharides (LPS) and capsular polysaccharides (CPS) (reviewed in reference [@B3]). Bacterial sialic acids have been shown to dampen host complement activity and neutrophil responses ([@B2], [@B4]) and to promote bacterial survival in the bloodstream and systemic dissemination to other tissues ([@B5]), especially when expressed at high levels. Sialic acid-modified surface structures are important for virulence in bloodstream and disseminated infections for well over a dozen pathogens ([@B6][@B7][@B13]). In contrast, many bacteria synthesize nine-carbon backbone sugars that do not meet the chemical definition of sialic acids, but the potential roles of these molecules in blood-borne diseases in mammals are not known.

Many bacteria synthesize nine-carbon backbone amino sugars, called legionaminic and pseudaminic acids, that are structurally similar to sialic acids ([@B1]). These molecules have been shown to play roles in motility and biofilm formation *in vitro* and in the chicken colonization and ferret diarrhea models *in vivo* ([@B14][@B15][@B16]). In fact, a growing body of evidence suggests that these acidic nine-carbon backbone amino sugars (collectively called nonulosonic acids, or NulOs) are widespread among prokaryotes, with ∼20% of sequenced prokaryotic genomes encoding a predicted nonulosonic acid biosynthetic (NAB) pathway ([@B1]). Collectively, these NulO molecules (including sialic acids) share an evolutionary origin, as evidenced by the fact that three enzymatic steps (Nab1, Nab2, and Nab3) of all NAB pathways are homologous across the three domains of life that synthesize them ([@B1]). Mammals do not synthesize legionaminic or pseudaminic acids.

Campylobacter jejuni is an interesting and well-studied example of a bacterium that synthesizes multiple types of NulOs---some strains can synthesize both sialic acids and sialic acid-like molecules ([@B14], [@B17], [@B18], [@B20], [@B21]). In some strains of C. jejuni, the LPS is capped with a sialic acid, while the unsheathed flagellum is modified with legionaminic and/or pseudaminic acid residues ([@B20], [@B21]). Mutations in key genes in the pseudaminic acid biosynthetic pathway of C. jejuni resulted in nonmotile phenotypes, defects in autoagglutination, and adherence to epithelial cells, as well as an attenuation of virulence, in a ferret diarrhea model ([@B14]). In contrast, mutations in the legionaminic acid biosynthetic gene cluster in C. jejuni did not have an impact on motility but led to decreased hydrophobicity, reduced biofilm formation, and a reduced ability to colonize the chicken intestine ([@B15]). Vibrio fischeri is another recent example in which legionaminic acid modifications present on LPS were shown to be important for motility and colonization of the bacterium\'s natural host, the Hawaiian bobtail squid ([@B16]).

Vibrio vulnificus is found in estuarine and coastal environments, both as a free-living bacterium and in association with a wide range of aquatic animals ([@B22]). Humans commonly come into contact with V. vulnificus via consumption of raw or undercooked shellfish, and this bacterium is the leading cause of seafood-related death in the United States; susceptible individuals have an alarming 50% case fatality rate ([@B23]). Vibrio vulnificus lethality appears to result from rapid progression of a localized infection (wound or gastroenteritis) to a systemic infection of the blood. However, little is known at the molecular level about virulence factors that allow V. vulnificus to survive in the bloodstream to cause this rapid-onset and commonly fatal disease.

Bioinformatic, phylogenetic, and biochemical analyses strongly suggest that V. vulnificus produces either the NulO legionaminic or pseudaminic acid but not the structurally similar sialic acid *N*-acetylneuraminic acid ([@B1], [@B19], [@B24]). Our previous study demonstrated that NulO molecules are expressed at some level by virtually all tested strains of V. vulnificus and suggested that clinical isolates are more likely to encode a NAB pathway genotype associated with higher levels of NulO expression ([@B24]). Here we sought to formally characterize the genetic basis for NulO biosynthesis in V. vulnificus, evaluate the significance of NulO production for motility and biofilm behaviors, and examine the hypothesis that these sialic acid-like molecules may also play a role in systemic pathogenesis. These studies implicate bacterial non-sialic acid NulO molecules in systemic mammalian pathogenesis for the first time and suggest that expression of these molecules in V. vulnificus also enhances its environmental fitness.

MATERIALS AND METHODS {#sec2}
=====================

Strains and culture conditions. {#sec2-1}
-------------------------------

This study utilized the V. vulnificus clinical isolates CMCP6 and YJ016. References to wild-type (WT) and Δ*nab2* strains are for strains with the CMCP6 background unless stated otherwise. Strains and plasmids used are listed in [Table 1](#T1){ref-type="table"}. All strains were grown aerobically at 30°C in Luria-Bertani broth (LB) (Fisher Scientific, Fair Lawn, NJ) containing 2% NaCl or in marine broth 2216 (MB) (BD, Franklin Lakes, NJ), as noted. Stationary-phase cultures were prepared with a single colony and allowed to grow for 16 h. A 2% inoculum of stationary-phase culture was used to grow 4-h logarithmic-phase cultures. Growth curves of strains were examined by measuring the optical density at 595 nm (OD~595~) every hour for 24 h, using a Sunrise microplate reader and Magellan plate reader software (Tecan US, Durham, NC). There were no significant differences in growth between WT and *nab* deletion strains. Streptomycin-resistant strains ([Table 1](#T1){ref-type="table"}), used only in the animal experiments, were obtained as follows. Strains were grown aerobically from a single colony at 30°C in 5 ml of LB plus 2% NaCl for 16 h. The overnight culture was concentrated by centrifugation at 4,000 × *g* for 10 min, and the resulting pellet was resuspended in 100 μl of LB plus 2% NaCl, plated on LB plus 2% NaCl plus 1,000 μg/ml streptomycin, and incubated for 24 h at 30°C. Resulting growth was replated on LB plus 2% NaCl plus 200 μg/ml streptomycin to isolate resistant colonies. Careful characterization of the resistant strains demonstrated the same phenotypes seen for the mutant strains (e.g., motility and biofilm defects). We also verified that the Δ*nab2* resistant strain did not vary in its *in vitro* growth characteristics from the streptomycin-sensitive Δ*nab2* or WT strain.

###### 

Bacterial strains and plasmids used in this study

  Strain or plasmid                 Genotype or description                                                                                                                            Reference or source
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Strains                                                                                                                                                                              
      Vibrio vulnificus strains                                                                                                                                                        
          CMCP6                     Clinical isolate                                                                                                                                   [@B54]
          YJ016                     Clinical isolate                                                                                                                                   [@B55]
          JBL0808 (Δ*nab2*)         CMCP6 Δ*nab2* (VV1_0808)                                                                                                                           This study
          JBL0808 (Δ*nab2*) Sm^r^   CMCP6 Δ*nab2*; spontaneously Sm-resistant isolate                                                                                                  This study
          JBL0808C                  CMCP6 Δ*nab2*/p*nab2* (pBB0808c)                                                                                                                   This study
          JBL0808C Sm^r^            CMCP6 Δ*nab2*/p*nab2* (pBB0808c); spontaneously Sm-resistant isolate                                                                               This study
          SAM0312 (Δ*nab2*)         YJ016 Δ*nab2* (VV0312)                                                                                                                             This study
          SAM0312 (Δ*nab2*) Sm^r^   YJ016 Δ*nab2* (VV0312); Sm-resistant isolate                                                                                                       This study
          JBL1950 (Δ*flhF*) Sm^r^   CMCP6 Δ*flhF* (VV1_1950); Sm-resistant isolate                                                                                                     This study
          JBL1950 (Δ*flhF*)         CMCP6 Δ*flhF* (VV1_1950)                                                                                                                           This study
      Escherichia coli strains                                                                                                                                                         
          DH5α λ-pir                *pir* ϕ80d*lacZ*ΔM15 δ(*lacZYA-argF*)*U169 recA1 hsdR17 deoR thi-1 supE44 gyrA96 relA1*                                                            
          β2155 DAP                 Donor for bacterial conjugation; *thr-1004 pro thi strA hsdS lacZ*ΔM15 (F *lacZ*ΔM15 *lacTRQJ36 proAB*) *dapA* Erm^r^ *pirRP4* (Km^r^ from SM10)   
  Plasmids                                                                                                                                                                             
      pJet1.2/blunt                 High-copy-number cloning vector                                                                                                                    
      pJet10808SOE                  V. vulnificus VV1_0808 (*nab2*) SOE product                                                                                                        This study
      pJet0312SOE                   V. vulnificus VV0312 (*nab1*) SOE product                                                                                                          This study
      pJet1950SOE                   V. vulnificus VV1_1950 (*flhF*) SOE product                                                                                                        This study
      pDS132                        Suicide plasmid; Cm^r^ *sacB*                                                                                                                      [@B30]
      pDS0808                       V. vulnificus *nab2* knockout vector (VV1_0808 SOE product)                                                                                        This study
      pDS0312                       V. vulnificus *nab1* knockout vector (VV0312 SOE product)                                                                                          This study
      pDS1950                       V. vulnificus *flhF* knockout vector (VV1_1950 SOE product)                                                                                        This study
      pBBR1MCS                      Expression plasmid; empty vector; Cm^r^                                                                                                            [@B56]
      pBB0808c                      *nab2* (VV1_0808) expression plasmid (p*nab2*)                                                                                                     This study

Allelic exchange mutagenesis and gene complementation in V. vulnificus. {#sec2-2}
-----------------------------------------------------------------------

V. vulnificus CMCP6 and YJ016 genome sequences were used for primer design, and oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA) ([Table 2](#T2){ref-type="table"}). An in-frame deletion mutant of the V. vulnificus CMCP6 *nab2* (VV1_0808) gene was constructed using splicing by overlap extension (SOE) PCR and allelic exchange ([@B29]), using the primers labeled SOEVV1_0808. A 411-bp deletion within the full-length, 1,002-bp *nab2* gene was constructed in the CMCP6 strain background as follows. Primers were designed (SOEVV1_0808A plus SOEVV1_0808B and SOEVV1_0808C plus SOEVV1_0808D) to PCR amplify two gene fragments that flank the targeted 411-bp deletion region within *nab2*. The fragments were annealed, ligated, and amplified using primers SOEVV1_0808A and SOEVV1_0808D to construct the 591-bp truncated *nab2* gene fragment. The truncated gene was inserted into the high-copy-number cloning vector pJET 1.2 A^R^ (Thermo Fisher Scientific, Waltham, MA) to generate pJet10808SOE, which was then transformed into the Escherichia coli cloning strain DH5α λ-pir. The cloned fragment was then subcloned from pJet10808SOE into the suicide vector pDS132 Cm^r^ ([@B30]) to generate the *nab2* knockout vector pDS0808. The knockout vector was then transformed into the diaminopimelic acid (DAP)-auxotrophic E. coli β2155 donor strain, which was conjugated to V. vulnificus by cross-streaking onto LB plates containing 0.3 mM DAP (Sigma-Aldrich, St. Louis, MO). Subsequent growth was plated on LB plus 2% NaCl plus 25 μg/ml chloramphenicol to isolate single-crossover recombinants of V. vulnificus containing pDS0808. V. vulnificus conjugants were cultured overnight without antibiotics to allow a second round of homologous recombination to occur, eliminating pDS0808 and producing an in-frame deletion mutant. The resulting overnight culture was plated onto LB plus 2% NaCl supplemented with 10% sucrose, which was lethal to members of the population still harboring a *sacB*-containing plasmid. A 396-bp deletion in the YJ016 *nab2* (VV0312) allele, a 420-bp deletion in CMCP6 *nab1*, and an 837-bp deletion in the CMCP6 *flhF* (VV1_1950) gene were also constructed as described above. Primers for these mutants are provided in [Table 2](#T2){ref-type="table"} and use the same naming convention as that shown for CMCP6 *nab2*. Deletion mutants were confirmed by PCR using SOE flanking primers and by sequencing. CMCP6 Δ*nab2* was complemented by amplifying the VV1_0808 gene, using primers VV1_0808Fc and VV1_0808Rc ([Table 2](#T2){ref-type="table"}). The gene was cloned into pBBR1MCS Cm^r^ to generate the complementation plasmid pBB0808c (p*nab2*). Selection for the complemented strain was achieved by plating on LB plus 2% NaCl plus 25 μg/ml chloramphenicol. It should be noted that the complementation strains displayed a moderate growth defect compared to the wild type, which could not be attributed to expression of the empty vector or to overexpression of Nab2, as the same effect was not observed for CMCP6 plus p*nab2*, CMCP6 plus empty vector or CMCP6 Δ*nab2* plus empty vector. Despite this growth defect, the complemented strain restored the *in vitro* phenotypes of the Δ*nab2* mutant and was able to outcompete the Δ*nab2* mutant *in vivo*.

###### 

Primers used for this study

  Primer name      Sequence (5′-3′)                                 *T~m~* (°C)   Product size (bp)
  ---------------- ------------------------------------------------ ------------- -------------------
  SOEVV1_0808A     TCTAGACGCCAAGCACCAAAGTTATT                       60            
  SOEVV1 0808B     CTCTTCGTCTGGCGTTGACA                             60            356
  SOEVV1_0808C     TGTCAACGCCAGACGAAGAGGCTAGCCTCGAGCCACAAGA         60            
  SOEVV1_0808D     GCATGCTCAAGTTGCGGATCATTTTG                       60            373
  SOEVV1_0808FLF   CCAGAGAAGAGGCACCAGTT                                           
  SOEVV1_0808FLR   CCAGAGAAGAGGCACCAGTT                             60            1,237
  SOEVV0312A       CTTATGGGCCAAGGTGATAGCAG                          61            
  SOEVV0312B       GGTCGAAAGGAACTCAATACCC                           61            402
  SOEVV0312C       GGGTATTGAGTTCCTTTCGACCGATTTACCTGCGGGTTACTCTG     60            
  SOEVV0312D       CTCGAGCATCTCCCAATACTG                            60            369
  SOEVV0312FLF     GTTACCTTGGGTGAAGAAGCAC                           60            
  SOEVV0312FLR     CACTTCAGCAAAGGAAGAGACC                           60            1,936
  SOEVV1_1950A     TCTAGATCGAATTGTACAGGCTGTGG                       60            
  SOEVV1_1950B     CAAAGCGTTTGGTCATGGAT                             61            399
  SOEVV1_1950C     ATCCATGACCAAACGCTTTGTCATGCAAGAGAGTGG GGAA        61            
  SOEVV1_1950D     GAGCTCGCTTGATCGTGTATCATATTCTCA                   59            377
  SOEVV1_1950FLF   AGGCGAACCAGCAGTCTTAC                             59            
  SOEVV1_1950FLR   GCCAAACCTAGGGTCACATT                             59            1,838
  SOEVV1_0803A     TCTAGAAAGCGTGCACAAGTGGATATTCTCA                  60            
  SOEVV1_0803B     AACGGCACCTCTGCCCCCGCT                            60            241
  SOEVV1_0803C     AGCGGGGGCAGAGGTGCCGTTAAGCTCGGTTGATATTGACCATGAG   56            
  SOEVV1_0803D     GAGCTCGCCCCACTCCACTTGCTGA                        56            227
  SOEVV1_0803FLF   GATTACTTCGGTGGCGAAAG                             60            
  SOEVV1_0803LFR   GAATCAGGTAACGTGGTGCT                             60            1,063
  VV1_0808Fc       AAGCTTCGCCAAGCACCAAAGTTATT                       60            
  VV1_0808Rc       TCTAGAGTGGCGGTGACTACACAGATT                      60            1,079

HPLC analysis of V. vulnificus NulOs. {#sec2-3}
-------------------------------------

Bacterial cultures were washed with phosphate-buffered saline (PBS) and subjected to mild acid hydrolysis in 2 N acetic acid at 80°C for 3 h, as previously described ([@B31]). After mild acid treatment to release NulO residues, cellular debris was removed by centrifugation, and a low-molecular-weight fraction was isolated by centrifugation through a 10,000-molecular-weight-cutoff filter (Vivaspin 500; Vivaproducts, Littleton, MA). The filtrate was derivatized with 1,2-diamino-4,5-methylene dioxybenzene (DMB), which is specific to the keto acid portion of NulO residues. Reaction mixtures consisted of 7 mM DMB, 18 mM sodium hydrosulfite, 1.4 M acetic acid, and 0.7 M 2-mercaptoethanol (Sigma-Aldrich) and were incubated in the dark at 50°C for 2 h. Derivatized NulO residues were resolved by high-pressure liquid chromatography (HPLC) using a C~18~ column (Tosoh Bioscience, King of Prussia, PA) and eluted isocratically using 85% Milli-Q ultrapure water, 8% acetonitrile, and 7% methanol at a rate of 0.9 ml/min for a period of 50 min, as previously described ([@B31]). Detection of fluorescent NulO derivatives was achieved using an excitation wavelength of 373 nm and an emission wavelength of 448 nm. 3-Deoxy-[d]{.smallcaps}-manno-octulosonic acid (Kdo) is an eight-carbon-backbone monosaccharide related to the nonulosonic acids that is a conserved component of the lipopolysaccharide core. Kdo is also released by mild acid hydrolysis and derivatized by DMB and thus served as a convenient internal positive control in the analyses and could also be used to calculate relative levels of NulO production.

Lipopolysaccharide analysis. {#sec2-4}
----------------------------

Lipopolysaccharide was analyzed by the method detailed by Amaro et al. ([@B32]), with minor modifications. Briefly, 1.5-ml log cultures grown in marine broth were adjusted to an OD~600~ of 0.8, centrifuged at 400 × *g* for 5 min, and resuspended in 50 μl of Laemmli buffer. Samples were boiled for 10 min, and 25 μg of proteinase K in 10 μl of Laemmli buffer was added and incubated at 60°C for 1 h. The extracted LPS was separated by SDS-PAGE on a 4 to 15% acrylamide gradient gel (Bio-Rad, Hercules, CA) and visualized by periodic acid oxidation, fluorescence labeling with Pro-Q Emerald 300 stain (Molecular Probes/Invitrogen, Carlsbad, CA), and imaging under UV light.

Antibiotic sensitivity. {#sec2-5}
-----------------------

Sensitivity to polymyxin B was assessed by assays of the zone of clearance. One-hundred-microgram aliquots of polymyxin B (Sigma) were applied to 1/4-in. sterile blank cellulose antibiotic susceptibility discs. The following antibiotic discs (BD) were used to determine the general sensitivity of the strains: tetracycline, 30 μg; ciprofloxacin, 5 μg; nalidixic acid, 30 μg; erythromycin, 15 μg; and gentamicin, 10 μg. Log-phase cultures were spread plated onto LB plus 2% NaCl and allowed to dry for 10 min, antibiotic discs were applied, and the plates were incubated at 30°C overnight. The assay was performed in duplicate or triplicate, followed by measurement of the zones of clearance by use of calipers.

V. vulnificus motility. {#sec2-6}
-----------------------

Motility was assessed by inoculating 1 μl of a log-phase culture (adjusted to an OD~600~ of 1.0) into the center of a 10-cm MB soft agar plate (0.3% agar). After incubation for 16 h at room temperature, the diameter of bacterial movement during growth was measured in millimeters by using calipers. Measurements were performed in triplicate, with at least two biological replicates for each.

Visualization and counting of V. vulnificus flagella. {#sec2-7}
-----------------------------------------------------

Transmission electron microscopy was used to visualize flagella and quantify the population with flagellar defects. V. vulnificus was cultured overnight at 30°C in MB, washed 3 times by centrifugation at 4,000 × *g*, and resuspended in Dulbecco\'s phosphate-buffered saline. Samples were allowed to adsorb to Formvar/carbon-coated copper grids for 10 min. Grids were washed in distilled H~2~O and stained with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 min. Excess liquid was gently wicked off, and grids were allowed to air dry. Samples were viewed on a JEOL 1200EX transmission electron microscope (JEOL USA, Peabody, MA) at an accelerating voltage of 80 kV. Flagellar phenotypes of 100 bacteria were counted for each strain in two independent experiments.

Biofilm assay. {#sec2-8}
--------------

The ability to form biofilms was assessed by inoculating 96-well plates with 1:100 dilutions of stationary cultures in MB, followed by incubation periods of up to 24 h at room temperature. The culture medium was removed, and the wells were washed three times with sterile PBS. One hundred microliters of 0.1% crystal violet was added to each well and incubated for 30 min at room temperature. Unbound crystal violet was then removed, and wells were washed three times with 100 μl of sterile PBS. Crystal violet was extracted using 100 μl of dimethyl sulfoxide (DMSO), and the OD~595~ was recorded. Biofilm assays were performed in triplicate, with at least two biological replicates for each.

Mouse infection model. {#sec2-9}
----------------------

Animal infection studies were performed in accordance with approved protocols from the Washington University Division of Comparative Medicine. Bacterial strains to be used in the competitive infections were grown overnight aerobically at 30°C in LB plus 2% NaCl. Overnight cultures were diluted 1:50 in fresh medium to grow samples to log phase. V. vulnificus strains used in each competition were washed in sterile PBS and normalized to an OD~600~ of 0.3 prior to preparation of the mixed strain inoculum. Male 8- to 10-week-old CD1 mice (Charles River, Wilmington, MA) were infected with 5 × 10^6^ to 1 × 10^7^ total CFU in 100 μl PBS by tail vein injection. Blood was collected from the submandibular vein at 30 and/or 90 min postinfection. The animals were sacrificed at 90 min postinfection, and in some experiments, the liver was harvested and homogenized in sterile PBS. Spontaneously streptomycin-resistant isolates of the CMCP6 Δ*nab2* mutant and Δ*nab2*/p*nab2* complemented strain were generated specifically for use in the *in vivo* competition experiments. The collected samples were serially diluted and plated on LB agar, with and without streptomycin (Sm) to distinguish WT from Δ*nab2* Sm^r^ mutant or Δ*nab2*/p*nab2* Sm^r^ colonies. The combination of chloramphenicol and streptomycin proved too toxic for the slow-growing Δ*nab2*/p*nab2* complemented strain (refer to "Strains and culture conditions," above); therefore, in competitions with the CMCP6 Δ*nab2* mutant, the Δ*nab2*/p*nab2* complemented strain was distinguished by its small colony size. The competitive index (CI) was determined as follows: CI = ratio out (WT/mutant)/ratio in (WT/mutant). A CI of \>1 indicates that the WT outcompeted the mutant.

RESULTS {#sec3}
=======

Establishment of the genetic basis for nonulosonic acid biosynthesis in V. vulnificus. {#sec3-1}
--------------------------------------------------------------------------------------

V. vulnificus CMCP6 and YJ016 contain phylogenetically distinct clusters predicted to be involved in the synthesis of NulO molecules. Three common steps of NAB pathways across the three domains of life are catalyzed by homologs of CMP-*N*-acetylneuraminic acid synthetase (Nab1), *N*-acetylneuraminic acid synthase (Nab2), and UDP-*N*-acetylglucosamine 2-epimerase (Nab3). HPLC analysis previously revealed that strains with a CMCP6-like genotype produced much larger amounts of NulO than those with a YJ016-like genotype ([@B24]). In fact, the *nab* clusters in these strains are highly divergent from one another, with no synteny and limited sequence identity ([Fig. 1A](#F1){ref-type="fig"}). In YJ016, the *nab* genes are on the positive strand, and in CMCP6, they are on the negative strand. Although the *nab* genes in V. vulnificus are related to genes encoding a sialic acid (*N*-acetylneuraminic acid), there is limited sequence identity between NAB pathway components in V. vulnificus and the more well-described enzymes involved in sialic acid synthesis in E. coli K1. For example, CMCP6 Nab1 shares only 38% amino acid identity (E value, 5e−34) with E. coli NeuA, Nab2 shares 44% identity (E value, 3e−91) with E. coli NeuB, and Nab3 shares 40% identity (E value, 9e−84) with E. coli NeuC.

![V. vulnificus *nab* genetic organization and role of *nab2* in NulO biosynthesis. (A) Schematic of the V. vulnificus NulO biosynthetic clusters in YJ016 and CMCP6. Open reading frames and the direction of transcription are designated by arrows. *nab1* (encoding a CMP-neuraminic acid synthase homolog), *nab2* (encoding an *N*-acetylneuraminic acid synthase homolog), and *nab3* (encoding a UDP-*N*-acetylglucosamine 2-epimerase homolog) are highlighted. Percentages in shaded areas indicate amino acid identities of translated genes. (B) DMB-HPLC analysis of the CMCP6 WT and isogenic Δ*nab2* and complemented (Δ*nab2+pnab2*) strains confirmed that *nab2* encodes the V. vulnificus NulO synthase. (C and D) NulO expression was normalized to that of 3-deoxy-[d]{.smallcaps}-manno-octulosonic acid (Kdo) for quantitative comparisons of NulO expression between strains. Error bars represent standard deviations for three experiments. One-way analysis of variance (ANOVA) with the Bonferroni multiple-comparison posttest (*P* \< 0.05) was used to examine the statistical significance of differences in NulO production. \*, *P* \< 0.05; \*\*\*\*, *P* \< 0.0001.](zii9990913200001){#F1}

To definitively determine the genetic basis for NulO production in V. vulnificus, we performed an in-frame deletion of the VV1_0808 synthase (*nab2*) in the V. vulnificus CMCP6 wild-type (WT) strain ([Fig. 1A](#F1){ref-type="fig"}). The Δ*nab2* mutant strain (JBL0808) did not exhibit any significant defects in growth *in vitro*. To determine the effect of deletion of *nab2* on NulO biosynthesis, NulO residues in the WT and Δ*nab*2 strains were released by mild acid hydrolysis and derivatized with the fluorescent molecule DMB, which reacts with the alpha-keto acid of NulOs. HPLC analysis of total cell-associated NulOs revealed a complete absence of NulO expression in the Δ*nab2* strain ([Fig. 1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). Complementation of the Δ*nab2* strain was accomplished by plasmid-based overexpression from the *nab2* plasmid to create strain JBL0808C, here referred to as the Δ*nab2*/p*nab2* strain ([Table 1](#T1){ref-type="table"}). Deletion of *nab2* in the YJ016 background also resulted in the elimination of NulO biosynthesis ([Fig. 1D](#F1){ref-type="fig"}). We note that NulO synthesis was restored in the Δ*nab2*/p*nab2* strain but that NulO levels were lower than the WT levels ([Fig. 1C](#F1){ref-type="fig"}). These analyses formally demonstrate the genetic basis for NulO synthesis in V. vulnificus, showing that the *N*-acetylneuraminic acid synthase homolog encoded by *nab2* is required for NulO biosynthesis.

V. vulnificus LPS is modified with NulO residues. {#sec3-2}
-------------------------------------------------

The LPS O antigen is a frequent site of NulO modification in Gram-negative organisms ([@B16], [@B29][@B30][@B31]). To investigate whether V. vulnificus LPS contains NulO residues, LPS was isolated from the WT and Δ*nab2* strains. Polyacrylamide gel electrophoresis followed by glycan visualization using the Pro-Q Emerald stain demonstrated a lower-molecular-weight band in the Δ*nab2* strains than in the WT strain ([Fig. 2A](#F2){ref-type="fig"}), suggesting a truncation of LPS. The higher-molecular-weight band seen with WT LPS was partially restored in the Δ*nab2*/p*nab*2 strain ([Fig. 2A](#F2){ref-type="fig"}). This finding is consistent with the intermediate levels of NulO measured in the Δ*nab2*/p*nab2* complemented strain ([Fig. 1C](#F1){ref-type="fig"}). The material used for electrophoresis was also subjected to fluorescence derivatization and HPLC analysis, verifying that NulOs were present in the LPS preparations (data not shown). In contrast, HPLC of flagellum subunits from isolated SDS-PAGE bands did not yield evidence of the presence of NulOs, despite the fact that positive controls analyzed in parallel (bacterial species known to produce glycosylated flagella) gave the expected result (data not shown). We note that a more sensitive detection method may be required to completely rule out the possibility of direct glycosylation of flagellar proteins in V. vulnificus.

![V. vulnificus LPS is modified with NulO, which contributes to polymyxin B resistance. (A) V. vulnificus LPS was analyzed by SDS-PAGE with staining of fluorescent glycans (Pro-Q Emerald 300). (B) Sensitivity to the cationic antimicrobial peptide polymyxin B was determined by measuring zones of clearance following overnight growth on plates with discs containing 100 μg of polymyxin B. \*\*\*\*, *P* \< 0.0001. (C) Resistance of V. vulnificus to other antibiotics.](zii9990913200002){#F2}

NulO modification of LPS contributes to the natural resistance of V. vulnificus to polymyxin B. {#sec3-3}
-----------------------------------------------------------------------------------------------

Polymyxins are a class of cationic antibiotics produced by Gram-positive bacteria that target LPS found in Gram-negative organisms. Polymyxins are considered one of the "last resort" antibiotics that can be used for infections with multidrug-resistant pathogens. Vibrio vulnificus is naturally resistant to polymyxin B; however, the basis for this resistance is not known ([@B36]). Based on the NulO modification of LPS, we investigated whether NulO residues on V. vulnificus influence the organism\'s sensitivity to polymyxin B by measuring the zones of clearance after bacterial growth around discs impregnated with the antibiotic. These experiments revealed that the Δ*nab2* strains (in both the CMCP6 and YJ016 backgrounds) had more pronounced zones of clearance than the WT strains (*P* \< 0.001) ([Fig. 2B](#F2){ref-type="fig"}), indicating an enhanced sensitivity to polymyxin B. Despite only partial restoration of NulO LPS modification, complementation (Δ*nab2*/p*nab2* strain) completely restored polymyxin B resistance. To determine whether the increased sensitivity of the Δ*nab2* strain to polymyxin B was specific or whether the mutation may have weakened the bacterial surface architecture, possibly allowing greater overall permeability, we examined the bacterial sensitivity to a broader range of antibiotics. These experiments demonstrated that the Δ*nab2* strain did not have increased susceptibility to tetracycline, ciprofloxacin, nalidixic acid, erythromycin, or gentamicin ([Fig. 2C](#F2){ref-type="fig"}). Together, these results strongly suggest that NulO modification of LPS shields V. vulnificus LPS from interaction with polymyxin B, thereby contributing to the natural resistance of V. vulnificus to this cationic antimicrobial peptide.

NulO residues play a role in the generation of V. vulnificus biofilms. {#sec3-4}
----------------------------------------------------------------------

Given the common involvement of bacterial surface carbohydrates in biofilm formation ([@B15], [@B33], [@B37][@B38][@B39]), we next evaluated the potential role of NulO biosynthesis in the ability of V. vulnificus to generate biofilms on abiotic surfaces. The results showed that in the CMCP6 background, *nab2* deletion resulted in a defect in biofilm formation compared to that of the WT ([Fig. 3A](#F3){ref-type="fig"}). Moreover, complementation (Δ*nab2/*p*nab2* strain) completely restored the ability to form biofilms ([Fig. 3A](#F3){ref-type="fig"}). These data implicate NulO molecules in the generation of V. vulnificus biofilms. However, in contrast to CMCP6, YJ016 (which expresses lower overall levels of NulOs) exhibited minimal, if any, *nab2*-dependent biofilm formation (not shown).

![NulO contributes to biofilm formation and motility. (A) Abiotic biofilm assays were conducted in 96-well polystyrene plates as described in Materials and Methods. At least 2 biological replicates were performed for each experimental condition. The data from the 6-h time point are shown. Error bars represent standard deviations. Statistical evaluation employed one-way ANOVA with the Bonferroni multiple-comparison posttest (*P* \< 0.05). (B and C) Swimming motility was assessed by placing aliquots of WT and isogenic Δ*nab*2 strains onto marine agar plates (0.3%) and measuring zones of motility following 16 h of growth at room temperature. The Δ*flhF* strain is a mutant of a known flagellar regulator that leads to a nonmotile, aflagellar strain. (D) Transmission electron micrographs of WT CMCP6 and its isogenic Δ*nab2* strain. (E) Flagellar morphology was assessed by electron microscopy. Several hundred individual bacteria were examined and showed that larger proportions of the Δ*nab2* population exhibited shortened or missing flagella. Error bars represent standard deviations. At least 2 biological replicates were tested for each experimental condition. One-way ANOVA with Dunnet\'s posttest was used to examine whether differences between the WT strain and isogenic derivatives were statistically significant. \*\*\*\*, *P* \< 0.0001; \*\*\*, *P* \< 0.001; \*\*, *P* \< 0.01 ; \*, *P* \< 0.05.](zii9990913200003){#F3}

Motility is reduced in V. vulnificus *nab* mutants. {#sec3-5}
---------------------------------------------------

Assessments of swimming motility revealed that mutations of NulO biosynthesis---in multiple strains and at multiple steps of the pathway---resulted in measurable reductions in motility ([Fig. 3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}). Notably, these strains are not nonmotile but rather exhibit a reduction of normal motility (see the comparison of the aflagellate Δ*flhF* strain to the Δ*nab* strains in [Fig. 3B](#F3){ref-type="fig"}). Visualization of flagellar filaments by transmission electron microscopy revealed that the deletion of *nab2* resulted in a missing or shortened flagellum ([Fig. 3D](#F3){ref-type="fig"} and [E](#F3){ref-type="fig"}). Although the vast majority (∼80%) of individual bacteria in the WT population produced a single long polar flagellum characteristic of this organism, the CMCP6 Δ*nab2* population contained a much larger proportion of individual bacteria with shortened or missing flagella, with only ∼23% of the population exhibiting a long polar flagellum ([Fig. 3D](#F3){ref-type="fig"}). Independent deletion of *nab2* in the YJ016 strain background had the same effect on flagellum morphology and motility ([Fig. 3D](#F3){ref-type="fig"}). Complementation of the motility phenotype was not possible by plasmid-based expression of the mutated genes. These results are consistent with the incomplete restoration of full NulO levels in the complemented versus WT strains ([Fig. 1C](#F1){ref-type="fig"}) and a corresponding intermediate phenotype of the LPS, with both lower- and higher-molecular-weight forms ([Fig. 2A](#F2){ref-type="fig"}). These data suggest a complex relationship between LPS structure and proper sheathing of the V. vulnificus flagellum, which will require further investigation. The fact that the Δ*nab2/*p*nab2* strain exhibited a complete restoration of polymyxin B resistance ([Fig. 2B](#F2){ref-type="fig"}) and biofilm formation ([Fig. 3A](#F3){ref-type="fig"}) despite its reduced motility clearly indicates that (i) NulO expression has biological effects that are independent of motility and (ii) we can use the mutant strains to distinguish motility-independent phenotypes.

NulO expression promotes bacterial survival in blood during systemic infection. {#sec3-6}
-------------------------------------------------------------------------------

To determine whether NulO molecules play a role in V. vulnificus systemic virulence, a tail vein injection model was used to directly administer bacteria to the bloodstream in CD1 mice. A spontaneously streptomycin-resistant isolate of the CMCP6 Δ*nab2* strain (Δ*nab2* Sm^r^) was generated specifically for use in these experiments to distinguish mutant from WT bacteria during competition *in vivo*. This strain retained the phenotypes observed for the Δ*nab2* strain and did not vary from the parental strain in its growth characteristics *in vitro* (not shown). Strains were set up to compete against each other in a pairwise fashion, using a 1:1 mixed inoculum, to examine relative fitness levels. Blood was drawn at early time points postinfection, and the numbers of CFU of the strains were determined based on differential resistance to streptomycin. These experiments revealed that the *nab2* gene confers a strong survival advantage to the WT strain in the bloodstream *in vivo*. The WT strain was present at approximately 5,000 CFU/ml of blood at 90 min postinfection, whereas the Δ*nab2* Sm^r^ strain was completely cleared by most animals at this time point ([Fig. 4A](#F4){ref-type="fig"}).

![Elaboration of NulO as a virulence factor during V. vulnificus bloodstream infection. (A to C) Animals were infected with approximately 10^7^ bacteria via the tail vein, using a 1:1 mixture of the strain pair shown in each panel (a spontaneously streptomycin-resistant isolate of the Δ*nab2* strain was utilized). Blood was drawn from the submandibular vein 90 min after infection, and serial dilutions were plated on selective media containing streptomycin or chloramphenicol to distinguish between competing strains, as described in Materials and Methods. (D) The competitive index was calculated as described in Materials and Methods and takes into account both the inoculum dose and 90-min blood titers for both strains. Data shown are for two independent experiments comparing the stated strain competitions in parallel, using 4 mice per group. The Mann-Whitney U test was used to examine statistical significance; \*, *P* \< 0.03, \*\*\*, *P* \< 0.001; ns, not statistically significant.](zii9990913200004){#F4}

Our observation that the Δ*nab2* strain displayed reduced motility compared to the WT strain required us not to rely solely on comparisons between the WT and Δ*nab2* strains to test the hypothesis that NulO expression may affect pathogenesis (since motility could also conceivably be a factor). To rule out the possibility that effects on motility contributed to the bloodstream survival phenotype *in vivo*, we also performed experiments in which the Δ*nab2* strain competed against the complemented Δ*nab2*/p*nab2* strain, which expresses NulO but retains the motility defect of the Δ*nab2* strain (see above). The results of this experiment demonstrated that plasmid-based complementation of *nab2* restored the ability of V. vulnificus to survive in the mammalian bloodstream ([Fig. 4B](#F4){ref-type="fig"}). This finding was echoed by the results of competition between the Δ*nab2* and Δ*nab2/*p*nab2* strains, which demonstrated that the complemented strain was significantly better able to survive in the bloodstream, exhibiting approximately 10-fold higher titers in blood than those of the Δ*nab2* strain 90 min after infection. To account for both input and output numbers of CFU of both strains and in each animal, a competitive index (CI) was calculated: values of \>1 indicate a relative fold increase in fitness of the WT versus the competing strain. In competition experiments between the WT and Δ*nab2* strains, the median CI at 90 min postinfection was 28.3 (range, 5.7 to 480.5) ([Fig. 4D](#F4){ref-type="fig"}). In contrast, in the Δ*nab2* complemented strain (Δ*nab2*/p*nab2*), there was an increase in the ability to compete against the WT strain, thus resulting in a significantly lower median CI (4.3; range, 0.484 to 49.2) than that for the WT and Δ*nab2* strain competition ([Fig. 4D](#F4){ref-type="fig"}). The median CI for animals infected with the Δ*nab2* and Δ*nab2/*p*nab2* strains was ∼10.7 (range, 0.667 to 77.4). Taken together, these data show that sialic acid-like NulO expression (independent of motility) contributes to the survival of V. vulnificus during systemic infection.

Higher levels of NulOs correspond to a greater ability to cause bloodstream infection and dissemination. {#sec3-7}
--------------------------------------------------------------------------------------------------------

We previously observed that V. vulnificus strains with a CMCP6-like *nab* genotype had approximately 100-fold higher levels of NulO expression than strains with a YJ016-like genotype ([@B24]) ([Fig. 5A](#F5){ref-type="fig"}). We next set out to measure the extent to which these two *nab* genotypes and their corresponding NulO phenotypes contribute to pathogenesis. To test the hypothesis that the CMCP6 strain may display a greater extent of *nab2*-dependent bloodstream survival and dissemination than YJ016, each of the WT strains were competed in parallel against their respective isogenic Δ*nab2* strains in the murine bacteremia model. Deletion of *nab2* in the YJ016 background significantly reduced bacterial survival at 90 min postinfection when this strain competed against the WT YJ016 strain. Head-to-head comparison of *nab2*-dependent bloodstream survival revealed a pronounced, ∼50-fold difference in the competitive index between the two strain backgrounds ([Fig. 5B](#F5){ref-type="fig"}). Whereas the CMCP6 strain outcompeted its Δ*nab2* derivative in the blood at 90 min postinfection, by about 500-fold (median, 508.3; *n* = 15), the YJ016 strain outcompeted its Δ*nab2* derivative by only about 10-fold (median, 11.22; *n* = 14). This finding strongly supports the interpretation that higher levels of NulO synthesis in connection with the CMCP6 *nab* genotype contribute to a greater capacity for bloodstream survival. These differences in *nab2*-dependent survival in blood *in vivo* also translate into differences in bacterial dissemination to other tissues, as evidenced by bacterial titers in the liver at 90 min postinfection (*P* \< 0.001) ([Fig. 5B](#F5){ref-type="fig"}).

![Relationship between CMCP6 and YJ016 NulO expression levels and *nab2*-dependent bacteremia with organ dissemination. (A) NulO expression levels were measured among environmental and clinical V. vulnificus isolates and expressed relative to the eight-carbon backbone monosaccharide Kdo. PCR was utilized to determine CMCP6-type or YJ016-type alleles of *nab2*. These data were previously published ([@B24]), and the results of a new analysis are shown here for comparison to panel B. (B) Animals were infected with approximately 10^7^ bacteria via the tail vein, using 1:1 mixtures of the WT reference strains YJ016 and CMCP6, each in competition with the Δ*nab2* mutant generated in the corresponding background. As described in the legend to [Fig. 4](#F4){ref-type="fig"}, these experiments utilized a spontaneously streptomycin-resistant isolate of the Δ*nab2* strain to distinguish between the strains. The Mann-Whitney U test was used to determine statistical significance. \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001. Data from four independent experiments were combined.](zii9990913200005){#F5}

DISCUSSION {#sec4}
==========

Vibrio vulnificus is a leading cause of food-related death in the United States due to its ability to quickly access the host bloodstream. However, virtually nothing is known about how this organism persists in the systemic vasculature during life-threatening systemic disease. Here we (i) formally elucidate the genetic basis of NulO biosynthesis in V. vulnificus, (ii) show that sialic acid-like modifications are present on bacterial LPS, (iii) demonstrate key roles for these molecules in behaviors and phenotypes likely to benefit the organism in its aquatic niche (e.g., antimicrobial resistance, biofilm formation, and motility), and (iv) demonstrate sialic acid-like molecules as the first virulence factor that promotes V. vulnificus survival during bloodstream infection *in vivo*.

Gene deletions at different steps of the NulO biosynthesis pathway in different V. vulnificus backgrounds led to measurable reductions in motility that could not be restored upon plasmid-based complementation. These motility defects may be due to alteration of the composition of the polar flagellum sheath, which has been shown in both V. cholerae and V. parahaemolyticus to contain LPS residues ([@B40]). Multiple lineages of Vibrionaceae express flagella that are sheathed with LPS ([@B40][@B41][@B42]). Moreover, a reduction or elimination of motility has been demonstrated upon alteration of the LPS O-antigen structure (via genetic manipulation) ([@B16], [@B43]) or through host antibody responses directed against the LPS O antigen ([@B44], [@B45]). For V. vulnificus, we demonstrated that NulO biosynthesis returns upon plasmid-based gene complementation. However, consistent with reduced NulO levels in the complemented versus WT strains, there was a significant amount of truncated LPS that remained. Unfortunately, the role of the sheath in flagellar function is largely unknown; some species contain a sheathed flagellum, whereas others do not. The apparent requirement of LPS O-antigen glycosylation for bacterial motility in several bacterial species with sheathed flagella requires additional study.

The mechanism by which NulO molecules promote survival of V. vulnificus *in vivo* is unknown at present. Sialic acid-like NulO molecules are structurally very similar to the canonical sialic acids and may act through similar mechanisms. Molecular mimicry of *N*-acetylneuraminic acid (the most common mammalian sialic acid) by bacterial pathogens has been studied and reviewed extensively ([@B3], [@B46][@B47][@B50]); thus, we provide only a few brief examples to illustrate how sialic acid-like molecules of V. vulnificus could result in enhanced bloodstream survival and dissemination. For example, sialic acid modifications of the LPS O antigens of Campylobacter jejuni, Neisseria meningitidis, and Haemophilus influenzae, the K1 (capsular) antigen of Escherichia coli, and the capsular polysaccharide of Streptococcus agalactiae have been shown to confer serum resistance and/or resistance to complement-mediated opsonization ([@B25], [@B26], [@B51][@B52][@B51]). Bacterial sialic acids have also been shown to interact with a family of sialic acid-binding, Ig-like lectin receptors known as Siglecs (recently reviewed in reference [@B27]). For example, terminal sialic acids of the capsular polysaccharide of Streptococcus agalactiae dampen immune responses by coopting Siglecs expressed on the surfaces of neutrophils and monocytes, resulting in a reduced bactericidal capacity ([@B2], [@B27], [@B28]). Future efforts will examine whether V. vulnificus sialic acid-like molecules protect against host immune responses by mechanisms similar to those of the canonical sialic acid-expressing pathogens.

Taken together, our results demonstrate that NulO residues modify LPS in V. vulnificus and contribute to the bacterium\'s motility, biofilm formation, and resistance to the cationic antimicrobial peptide polymyxin B. Moreover, our studies of systemic virulence in a mouse intravenous infection model provide the first demonstration that NulO molecules resembling host sialic acids are an important virulence factor promoting survival of V. vulnificus in the bloodstream. These studies highlight the importance of NulO molecules in the biology of V. vulnificus in its aquatic niche and suggest that the enhanced virulence brought about by these molecules in mammals may be purely accidental. Nevertheless, the results of these studies strongly suggest that strains possessing high levels of NulOs may be more dangerous to susceptible individuals. Thus, technologies able to identify strains with high-level NulO expression could prove useful for safety monitoring of oysters and other shellfish or the waters from which they are harvested.
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